Elevated soluble CD23 levels in the sera from patients with localized scleroderma

Archives of Dermatological Research

Volumn 288, Issue 2, 1996, Pages 74-78

  Sato, Shinichi ^a   Fujimoto, Manabu ^a   Kikuchi, Kanako ^a   Ihn, Hironobu ^a   Tamaki, Kunihiko ^a   Takehara, Kazuhiko ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

Author keywords

Antihistone antibody; CD23; Localized scleroderma

Indexed keywords

AUTOANTIBODY; CD23 ANTIGEN; HISTONE ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; RHEUMATOID FACTOR;

ADOLESCENT; ADULT; ANTIBODY TITER; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE ACTIVATION; BLOOD LEVEL; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ETIOLOGY; HUMAN; MUSCLE DISEASE; PRIORITY JOURNAL; SCLERODERMA;

EID: 0030071085     PISSN: 03403696     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02505047     Document Type: Article

References (34)

1. Takehara K, Moroi Y, Nakabayashi Y, Ishibashi Y (1983) Antinuclear antibodies in localized scleroderma. Arthritis Rheum 26:612-616
2. Ruffatti A, Peserico A, Glorioso S, Fiocco U, Rossi L, Gambari P, Todesco S (1986) Anticentromere antibody in localized scleroderma. J Am Acad Dermatol 15:637-642
3. Falanga V, Medsger TA Jr, Reichlin M, Rodnan GP (1986) Linear scleroderma: clinical spectrum, prognosis, and laboratory abnormalities. Ann Intern Med 104:849-857
4. Falanga V, Medsger TA Jr, Reichlin M (1987) Antinuclear and anti-single-stranded DNA antibodies in morphea and generalized morphea. Arch Dermatol 123:350-353
5. Kikuchi K, Takehara K, Ishibashi Y (1989) Antinuclear antibodies in localized scleroderma: unique staining in chromosome spreads. J Am Acad Dermatol 21:1301-1303
6. Sato S, Ihn H, Soma Y, Igarashi A, Tamaki T, Kikuchi K, Ishibashi Y, Takehara K (1993) Antihistone antibodies in patients with localized scleroderma. Arthritis Rheum 36:1137-1141
7. Scarola JA, Shulman LE (1975) Serologic abnormalities and their significance in localized scleroderma. Arthritis Rheum 18: 52
8. Falanga V, Medsger TA Jr, Reichlin M (1985) High titers of antibodies to single-stranded DNA in linear scleroderma. Arch Dermatol 121:345-347
9. Takehara K, Kikuchi K, Soma Y, Igarashi A, Ishibashi Y (1990) Anti-single-stranded DNA antibody and muscle involvement in localized scleroderma. Arch Dermatol 126:1368-1369
10. Sato S, Fujimoto M, Ihn H, Kikuchi K, Takehara K (1994) Antigen specificity of antihistone antibodies in localized scleroderma. Arch Dermatol 130:1273-1277
11. Ihn H, Sato S, Fujimoto M, Kikuchi K. Takehara K (1995) Demonstration of interleukin-2, interleukin-4 and interleukin-6 in sera from patients with localized scleroderma. Arch Dermatol Res 287:193-197
12. Delespesse G, Suter U, Mossalayi D, Bettler B, Sarfati M, Hofstetter H, Kilcherr E, Debre P, Dalloul A (1991) Expression, structure, and function of the CD23 antigen. Adv Immunol 49: 149-191
13. Yukawa K, Kikutani H, Owaki H, Yamasaki K, Yokota A, Nakamura H, Barsumian EL, Hardy RR. Suemura M, Kishimoto T (1987) A B cell-specific differentiation antigen, CD23, is a receptor for IgE (FcεR) on lymphocytes. J Immunol 138: 2576-2580
14. Kikutani H, Suemura M, Owaki H, Nakamura H, Sato R, Yamasaki K, Barsumian EL, Hardy RR, Kishimoto T (1986) Fcε receptor, a specific differentiation marker transiently expressed on mature B cells before isotype switching. J Exp Med 164: 1455-1469
15. Sarfati M, Nutman T, Fonteyn C, Delespesse G (1986) Presence of antigenic determinants common to Fc IgE receptors on human macrophages, T and B lymphocytes and IgE-binding factors. Immunology 59:569-575
16. Joseph M, Capron A, Ameisen JC, Capron M, Vorng H, Pancre V, Kusnierz JP, Auriault C (1986) The receptor for IgE on blood platelets. Eur J Immunol 16:306-312
17. Capron M, Capron A, Dessaint JP, Torpier G, Johansson SGO, Prin L (1981) Fc receptors for IgE on human and rat eosinophils. J Immunol 126:2087-2092
18. Letellier M, Nakajima T, Pulido-Cejudo G, Hofstetter H, Delespesse G (1990) Mechanism of formation of human IgE-binding factors (soluble CD23). III. Evidence for a receptor (FcεRII)- associated proteolytic activity. J Exp Med 172:693-700
19. Delespesse G. Sarfati M, Hofstetter H (1989) Human IgE binding factors. Immunol Today 10: 159-164
20. Gordon J, Flores-Romo L, Cairns JA, Millsum MJ, Lane PJ, Johnson GD, MacLennan ICM (1989) CD23: a multi-functional receptor/lymphokine? Immunol Today 10: 153-157
21. Armitage RJ, Goff LK, Beverley PCL (1989) Expression and functional role of CD23 on T cells. Eur J Immunol 19:31-35
22. Flores-Romo L, Cairns JA, Millsum MJ, Gordon J (1989) Soluble fragments of the low-affinity IgE receptor (CD23) inhibit the spontaneous migration of U937 monocytic cells: neutralization of MIF-activity by a CD23 antibody. Immunology 67: 547-549
23. Sarfati M, Delespesse G (1988) Possible role of human lymphocyte receptor for IgE (CD23) or its soluble fragments in the in vitro synthesis of human IgE. J Immunol 141:2195-2199
24. Mossalayi MD, Lecron JC, Dalloul AH, Sarfati M, Bertho JM, Hofstetter H, Delespesse G, Debre P (1990) Soluble CD23 (FcεRII) and interleukin 1 synergistically induce early human thymocyte maturation. J Exp Med 171:959-964
25. Liu Y-J, Mason DY, Johnson GD, Abbot S, Gregory CD, Hardie DL, Gordon J, MacLennan ICM (1991) Germinal center cells express bcl-2 protein after activation by signals which prevent their entry into apoptosis. Eur J Immunol 21:1905-1910
26. Sato S, Fujimoto M, Ihn H, Kikuchi K, Takehara K (1994) Clinical characteristics associated with antihistone antibodies in patients with localized scleroderma. J Am Acad Dermatol 31: 567-571
27. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1983) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 26:612-616
28. LeRoy EC, Black C, Fleischmajer P, et al (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202-205
29. Chomarat P, Briolay J, Banchereau J, Miossec P (1993) Increased production of soluble CD23 in rheumatoid arthritis, and its regulation by interleukin-4. Arthritis Rheum 36:234-242
30. Gordon J (1991) CD23: novel disease marker with a split personality. Clin Exp Immunol 86:356-359
31. Becker H, Potyka P, Weber C, Federlin K (1991) Detection of circulatig FcεR2/CD23+ monocytes in patients with rheumatic diseases. Clin Exp Immunol 85:61-65
32. Bansal A, Roberts T, Hay EM, Kay R, Pumphrey RSH, Wilson PB (1992) Soluble CD23 levels are elevated in the serum of patients with primary Sjögren's syndrome and systemic lupus erythematosus. Clin Exp Immunol 89:452-455
33. Matsumoto T, Miike T, Yamaguchi K, Murakami M, Kawabe T, Yodoji J (1991) Serum levels of soluble IL-2 receptor, IL-4 and IgE-binding factors in childhood allergic diseases. Clin Exp Immunol 85:288-292
34. Yanagihara Y, Sarfati M, Marsh D, Nutman T, Delespesse G (1990) Serum levels of IgE-binding factor (soluble CD23) in diseases associated with elevated IgE. Clin Exp Allergy 20: 395-401